Name | Bafetinib |
Synonyms | Lyn-IN-1 bafetinib Bafetinib Bafetinib analog (S)-N-(3-(5,5'-Bipyrimidin-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)-pyrrolidin-1-yl)me (S)-N-(3-([5,5'-bipyriMidin]-2-ylaMino)-4-Methylphenyl)-4-((3-(diMethylaMino)pyrrolidin-1-yl)Methyl)-3-(trifluoroMethyl)benzaMide N-[3-([5,5'-Bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)benzamide N-{3-[([5,5'-bipyrimidin]-2-yl)amino]-4-methylphenyl}-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide Benzamide, N-[3-([5,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)- |
CAS | 887650-05-7 859217-05-3 859212-16-1 |
EINECS | 1312995-182-4 |
Molecular Formula | C30H31F3N8O |
Molar Mass | 576.62 |
Density | 1.36 |
Melting Point | >166°C (dec.) |
Solubility | DMSO, Methanol |
Appearance | Solid |
Color | Yellow |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
Physical and Chemical Properties | Appearance: white or white-like crystalline powder Dissolution: dissolved in DMSO (up to 100 mM) Preservation: 3 years -20 ℃ powder Figure 1 shows bafitinib |
Use | Bafetinib (INNO-406) is an effective, selective, Bcr-Abl/Lyn dual inhibitor with IC50 of 5.8 nM/19 nM. It has no inhibitory effect on phosphorylation of T315I mutant, and has a slightly weaker effect on PDGFR and c-Kit. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.734 ml | 8.671 ml | 17.342 ml |
5 mM | 0.347 ml | 1.734 ml | 3.468 ml |
10 mM | 0.173 ml | 0.867 ml | 1.734 ml |
5 mM | 0.035 ml | 0.173 ml | 0.347 ml |